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a  b  s  t r  a  c  t
Frailty  is  a common  negative  consequence  of  ageing.  Sarcopenia,  the  syndrome  of loss  of  muscle  mass,
quality and  strength,  is  more  common  in  older  adults  and  has been  considered  a precursor  syndrome  or
the physical  manifestation  of frailty.  The  pathophysiology  of both  syndromes  is  incompletely  described
with  multiple  causes,  inter-relationships  and  complex  pathways  proposed.  Age-associated  changes  to
the immune  system  (both  immunesenescence,  the  decline  in immune  function  with  ageing,  and  inﬂam-
mageing,  a state  of  chronic  inﬂammation)  have  been  suggested  as  contributors  to  sarcopenia  and  frailty
but a direct  causative  role  remains  to  be  established.  Frailty,  sarcopenia  and  immunesenescence  are
commonly  described  in older  adults  but are  not  ubiquitous  to  ageing.  There  is evidence  that  all  three  con-
ditions  are  reversible  and all three  appear  to share common  inﬂammatory  drivers.  It  is  unclear  whether
frailty,  sarcopenia  and  immunesenescence  are  separate  entities  that co-occur  due  to  coincidental  or
potentially  confounding  factors,  or whether  they  are  more  intimately  linked  by the  same  underlyingnactivity cellular  mechanisms.  This  review  explores  these  possibilities  focusing  on  innate  immunity,  and  in partic-
ular associations  with  neutrophil  dysfunction,  inﬂammation  and known  mechanisms  described  to  date.
Furthermore,  we  consider  whether  the age-related  decline  in immune  cell  function  (such as neutrophil
migration),  increased  inﬂammation  and  the dysregulation  of  the phosphoinositide  3-kinase  (PI3K)-Akt
pathway  in neutrophils  could  contribute  pathogenically  to  sarcopenia  and  frailty.
©  2017  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license
(http://creativecommons.org/licenses/by/4.0/).
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1.1. FrailtyThe concept of frailty is probably recognised by most biogeron-
tologists but its emerging importance as a hallmark of ageing has
led to a more rigorous medical deﬁnition of physical frailty.
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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‘A medical syndrome with multiple causes and contributors that
s characterized by diminished strength, endurance, and reduced
hysiologic function that increases an individual’s vulnerability
or developing increased dependency and/or death’ (Morley et al.,
013).
This deﬁnition describes the syndrome but does not attempt to
nterpret the condition or its underlying biological mechanisms.
wo intrinsically different models of frailty have been proposed
n an attempt to operationalise the syndrome. The ﬁrst model,
he frailty phenotype model, was proposed by Fried and col-
eagues (Fried et al., 2001). This suggests that a step-wise increase
n self-reported disability is analogous with an increasing frailty
tate and correlates with adverse health outcomes such as death,
ospitalisation and falls. Fried demonstrates that the presence
f 3 components, out of a total of 5 (unintentional weight loss,
elf-reported exhaustion, weakness, slow walking speed and low
hysical activity), has predictive power in identifying mortality
isk. Fried extrapolates this to suggest that the presence of 3 com-
onents in a person identiﬁes them as frail and the presence of
 or 2 components as pre-frail (Fried et al., 2001). The model has
een validated by Fried and independent groups with concurrent
r predictive validity assessed in 17 different samples or cohorts
Bouillon et al., 2013), but no attempt has been made to assess the
eliability of the phenotype.
Conversely Rockwood et al. suggested that frailty was not a cat-
gorical phenomenon but best described as a dynamic, continuous
rocess of deﬁcit accumulation and as a result they proposed the
railty Index (Mitnitski et al., 2001). The most striking difference
ith the Fried deﬁnition of frailty was that any variable could be
onsidered a deﬁcit as long as it was associated with adverse health
utcomes, increased in prevalence with age into the tenth decade
nd had a prevalence of at least 1% which did not saturate in older
ge. Using this model Rockwood showed there was a greater corre-
ation of time to death with frailty index rather than age (Mitnitski
t al., 2001). The Frailty Index has also been widely tested for valid-
ty with concurrent or predictive validity assessed in 13 different
amples or cohorts (Bouillon et al., 2013), but not reliability.
One of the difﬁculties in deciding upon the most elegant and
linically applicable model is that each model describes a slightly
ifferent population. The Frailty Index has better discriminatory
bility for adults with moderate and severe frailty (Rockwood et al.,
007). This is probably due to its broader approach to the diagnosis
f frailty and the inclusion of cognitive and psychosocial markers
ather than solely relying on physical markers. There are also higher
ates of frailty reported with the Frailty Index, likely due to the
ontinuous nature of the model (Song et al., 2010). This may  make
t a better objective marker of the assessment of the efﬁcacy of an
ntervention. The frailty phenotype may  have utility in identifying
lder adults at risk of disability. It has been suggested that these
ssessment instruments should not be considered as alternatives,
ut rather as complementary.
Both the Frailty Index and the Frailty Phenotype are utilised in
esearch but the more global concept of frailty as described by the
railty Index is probably better accepted in the gerontology com-
unity. This is reﬂected in recent diagnostic and screening tools,
dmonton Frail Scale and PRISMA 7, including the assessment of
everal domains of health (Rolfson et al., 2006; Raiche et al., 2008).
owever, the relative ease of utilising the Frailty Phenotype means
t is still used in research as a method of identiﬁcation of frailty.
.2. SarcopeniaSarcopenia can be considered as one of the main physical drivers
f frailty or perhaps even a precursor state if it is present without a
edical classiﬁcation of frailty as described above. As with frailty,
eﬁnitions of sarcopenia have evolved over time reﬂecting greater Reviews 36 (2017) 1–10
understanding of the condition. The current broadly accepted def-
inition includes the effects on function as well as including muscle
mass and strength:
‘A syndrome characterised by progressive and generalised loss
of skeletal muscle mass and strength with a risk of adverse out-
comes such as physical disability, poor quality of life and death.’
(Cruz-Jentoft et al., 2010a).
Similar to the frailty phenotype the European Working Group
on Sarcopenia in Older People (EWGSOP) recommend categorising
sarcopenia into pre-sarcopenia, sarcopenia, and severe sarcopenia
depending on the presence of certain criteria. They suggest that
the pre-sarcopenia stage is characterised by low muscle mass with
no impact on muscle strength or physical performance, whereas
the sarcopenia stage is low muscle mass with either low muscle
strength or low physical performance and severe sarcopenia is the
presence of all three criteria (Cruz-Jentoft et al., 2010a).
The cut off point for each criterion is not currently standardised
and is dependent on both the method of measurement and the
researcher. It is generally accepted that low physical performance is
deﬁned as a gait speed of less than 0.8m/sec. Low muscle strength is
usually deﬁned by handgrip strength of less than 30 kg for men and
less than 20 kg for women (Cruz-Jentoft et al., 2010a; Cruz-Jentoft
et al., 2010b). Low muscle mass is usually measured by a skeletal
muscle mass index with a variety of cut offs quoted in the literature
ranging from 7.23 kg/m2 to 8.87 kg/m2 in men  and 5.45 kg/m2 to
6.42 kg/m2 in women (Baumgartner et al., 1998; Newman et al.,
2003; Chien et al., 2008; Cruz-Jentoft et al., 2010a). The diversity
in the cut offs, particularly in deﬁning low muscle mass, utilised
in research has led to huge disparity in the prevalence of reported
low muscle mass with prevalence reported as between 3.3 to 41.5%
in community populations over 65 (von Haehling et al., 2010). This
has been recognised by the EWGSOP who have recommended that
more research is urgently needed in order to obtain good reference
values for populations around the world.
The inclusion of both muscle mass and strength within the deﬁ-
nition of sarcopenia has partially occurred in response to extensive
research which has shown that whilst loss of muscle mass is asso-
ciated with loss of muscle strength, the relationship is not linear;
the decline in strength is more rapid than the concomitant loss
of muscle mass. Goodpaster et al. demonstrated in a community
dwelling population aged between 70 and 79 that muscle mass
declines at 0.5-2% per annum compared to 2–4% loss of muscle
strength (Goodpaster et al., 2006). Thus age-related changes in the
quality of the muscle may  be as important as the reduced mass
and reduced muscle quality, notably loss of type II ﬁbres, reduced
mitochondrial mass and increased fat inﬁltration, may  contribute
to loss of muscle strength and power (Narici and Maffulli, 2010).
Potentially a more inclusive deﬁnition of sarcopenia may incorpo-
rate the loss of muscle mass, reduced muscle quality and a loss of
functional strength, as shown in Fig. 1, which depicts age-related
changes occurring within the muscle from the whole muscle level
through to a cellular level and how these contribute to the loss of
muscle mass, quality, strength and power.
1.3. Relationships between frailty and sarcopenia
The relationship between frailty and sarcopenia is not yet fully
characterised but these conditions share many of the same clini-
cal outcomes, associations and suggested pathophysiology. Despite
this, sarcopenia is considered a component of frailty but frailty
is not considered a component of sarcopenia. However, there is
considerable overlap between the deﬁning criteria of the Frailty
Phenotype and sarcopenia. Severe sarcopenia as deﬁned by EWG-
SOP is pre-frailty by the Fried phenotype. Sarcopenia is often
considered a pre-cursor syndrome or the physical component to
frailty.
D. Wilson et al. / Ageing Research Reviews 36 (2017) 1–10 3
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Sarcopenia is reported to be twice as common as frailty in the
eneral population (von Haehling et al., 2010). The prevalence of
oth conditions is dependent on population and deﬁnition. Using
he EWGSOP deﬁnition and criteria of sarcopenia the prevalence
anges from 4.6%, community dwelling men  in the UK aged 68–76
Patel et al., 2014), to 68%, male Italian nursing home residents over
0 (Landi et al., 2012). A recent systematic review of frailty preva-
ence in a community population (Collard et al., 2012) reported
he range to be 4.0%, independently mobile men  over 65 (Cawthon
t al., 2007), to 59.1%, community dwelling Dutch older than 70
Metzelthin et al., 2010). The calculated weighted average of frailty
s deﬁned using the Frailty Phenotype is 9.9% (Collard et al., 2012).
Research has shown that in frail community dwelling adults
he most common positive Fried criteria was slow gait speed (43%)
nd weakness (54%), the functional deﬁning criteria of sarcopenia
Rothman et al., 2008). It has also been reported that the relative
isk of developing weakness and low activity was  higher than devel-
ping any other frailty deﬁning criteria over 7.5 years of follow up
n initially non-frail women (Xue et al., 2008). This suggests that
heoretically while it is possible to have frailty without sarcopenia
linically it is unlikely. However, a recent isolated report investigat-
ng the concordance of frailty and sarcopenia demonstrated that
railty was more common than sarcopenia and the concordance
etween frailty and sarcopenia was poor (Reijnierse et al., 2016).
his is the only literature investigating the concordance of frailty
nd sarcopenia but is contrary to previous understanding and an
solated report.
Importantly both frailty and sarcopenia are considered partly
eversible conditions. Several epidemiological studies have shown
hat whilst transition between lesser and greater frailty is always
he most frequent outcome, a number of participants will transi-
ion from greater to lesser frailty (Gill et al., 2006; Fallah et al., 2011;
spinoza et al., 2012; Lee et al., 2014). Health status and baseline
unction is important, as those with poor mobility at baseline in a
ongitudinal study experienced faster acceleration of their frailty
han those with good mobility (Fallah et al., 2011). The reversal of
railty has also been demonstrated in intervention studies. A mul-
ifactorial intervention in community dwelling frail adults resulted
n a signiﬁcant difference in frailty prevalence between the twoed changed occurring within the muscle from a whole muscle level through to a
ectional area.
groups who were identical at baseline. Of note, the intervention was
speciﬁc to the individual depending on their positive frailty criteria
at baseline assessment, for example those scoring for weight loss
would be assessed and managed by a dietician, consistent with a
personalised medicine approach. Importantly, this study reported
an actual reduction in diagnosis of frailty in the intervention group
not just a slowing of progression (Cameron et al., 2013). It is also
possible to improve components of frailty and sarcopenia. Several
resistance exercise programmes have documented improvements
in gait speed and strength in groups of frail older adults, with pro-
grammes of 8–12 weeks able to reverse loss of muscle strength
equivalent to that lost over 20 years (Fiatarone et al., 1994; Liu-
Ambrose et al., 2004). Improved understanding of the processes
underlying sarcopenia may  allow the development of even more
efﬁcacious and targeted interventions.
2. Pathophysiology of sarcopenia and frailty
The pathophysiology of both sarcopenia and frailty is com-
plex. Proposed models for both syndromes incorporate multiple
causes, inter-relationships and elaborate pathways (Fried et al.,
2009; Cruz-Jentoft et al., 2010a). However, both syndromes are
incompletely characterised and there is insufﬁcient understanding
of the underlying cellular mechanisms driving the development
and maintenance of states of frailty and sarcopenia. Sarcopenia is
better understood than frailty largely due to its effects being con-
centrated on a single system, the neuromuscular system, and for
this reason it has been suggested as a physical model of frailty.
2.1. Regulation of muscle mass
Our current understanding of the regulation of muscle mass is
predominately based on data from animal studies, with much less
known of the key regulatory processes in human muscle. Stud-
ies in rodents suggest that muscle synthesis is intrinsically linked
with muscle atrophy via the PI3k-Akt pathway which is central to
both processes (Schiafﬁno and Mammucari, 2011). Muscle synthe-
sis is activated by insulin-like growth factor 1 (IGF-1) binding to
4 D. Wilson et al. / Ageing Research Reviews 36 (2017) 1–10
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ole  for inﬂammaging within the creation and maintenance of frailty and sarcopeni
GF-1 receptor which triggers the activation of a signalling path-
ay including PI3k, Akt, and the mammalian target of rapamycin
mTOR), which in turn phosphorylates S6 kinase and other fac-
ors which promote protein synthesis (Schiafﬁno and Mammucari,
011). There are multiple modulators of the pathway, both intrin-
ic and extrinsic. Intrinsic regulators include S6 kinase 1 inhibition
f insulin receptor substrate (IRS) (Harrington et al., 2004) and
TORC2 upregulation of Akt (Sarbassov et al., 2005). Extrinsic reg-
lators include: amino acids which can directly activate mTORC1
Kim et al., 2008; Sancak et al., 2008) and beta adrenergic agents
Kline et al., 2007) and Wnt7a which both upregulate the PI3k-Akt
athway (von Maltzahn et al., 2012).
Muscle atrophy via both the ubiquitin proteasome pathway
nd autophagy lysosomes is centrally regulated by forkhead box
roteins (FoxO). FoxO when present in the nucleus induces the
biquitin E3 ligases atrogen-1 and muscle RING ﬁnger protein-1
MuRF-1) (Williamson et al., 2010) which cause myoﬁbril degrada-
ion. FoxO also regulates ATG genes which promote mitochondrial
egradation via autophagy (Polager et al., 2008). As expected there
re multiple modulators of these pathways and arguably the most
mportant is the effect of Akt on FoxO: Akt phosphorylates FoxO and
ransports it from the nucleus to the cytoplasm preventing it from
nducing either E3 ligases or ATG genes (Stitt et al., 2004; Huang
nd Tindall, 2007; Jang et al., 2007). Myostatin, via the action of
mad 2 and 3, upregulates FoxO (McFarlane et al., 2006) and mus-
le disuse produces neuronal nitric oxide synthase (nNOS) which
nhances FoxO3 mediated transcription of E3 ligases (Suzuki et al.,
007).
The majority of studies investigating sarcopenia in humans
ave suggested that loss of muscle mass is primarily driven by a
lunted synthetic response to both feeding and exercise, termed
nabolic resistance (Murton and Greenhaff, 2009; Markofski et al.,posed model of inﬂammaging, frailty and sarcopenia. The model describes a central
es.
2015; Wall et al., 2015). Moreover, there is little data to suggest
that atrogenes or ubiquitin proteasomal degradative pathways are
enhanced in older adults, indeed in the fasted state (when pro-
tein breakdown is at its highest) there is no difference in protein
turnover or signalling through synthetic pathways such as Akt
between young and old adults (Francaux et al., 2016).
Anabolic and catabolic pathways may  be relevant in periods of
extreme inactivity, such as bed rest, and in chronic inﬂammatory
states, such as chronic obstructive pulmonary disease (COPD). In
a recent 5 day bed rest study in well characterised healthy young
and old subjects, leg lean mass and strength were reduced only
in the old subjects. Both subject groups had blunted mTORC1 sig-
nalling and increased MURF1 expression in skeletal muscle after
bed rest, but only the older group had reduced amino acid induced
protein synthetic rates and increased atrogene expression (Tanner
et al., 2015). A study investigating the effect of resistance train-
ing in participants with COPD, a chronic inﬂammatory condition,
demonstrated higher levels of MAFbx and MURF1 protein expres-
sion (atrogenes) and increased phosphorylation of p70s kinases
(Constantin et al., 2013). These studies suggest a decrease in mus-
cle synthesis and an increase in muscle degradation (dysregulated
muscle homeostasis) is seen with inactivity and chronic inﬂamma-
tory conditions.
Patients with sepsis are subject to both periods of extreme
inactivity and a pro-inﬂammatory state and could therefore be
considered a model of accelerated ageing (Singer et al., 2016). Fol-
lowing sepsis and admission to critical care 70–100% of patients
reported prolonged weakness (Callahan and Supinski, 2009) which
is due both to muscle loss and changes in muscle cell functionality.
This group deserves further study for a link between inﬂammation
and sarcopenia.
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. Ageing of the immune system
The decline in immune function with age, termed immunese-
escence, is well documented and includes increased susceptibility
o infections, reduced vaccination responses in older adults and
ncreased risk of chronic inﬂammatory diseases such as Rheuma-
oid Arthritis (Weng, 2006; Shaw et al., 2010; Goronzy and Weyand,
013). The many changes that occur in the components of the
mmune system with age have been reviewed previously (Gruver
t al., 2007; Ongradi and Kovesdi, 2010; Shaw et al., 2010) and we
ill thus consider only those elements of innate immunity that
ould contribute to frailty and sarcopenia, primarily through their
ole in inﬂammation.
Immunesenescence includes inﬂammaging,  the increased pres-
nce of a low-grade chronic systemic pro-inﬂammatory state with
ge (Franceschi et al., 2000; Baylis et al., 2013b). Inﬂammaging is
haracterised by increased levels (typically 2–4 fold those seen in
ealthy young subjects), of pro-inﬂammatory cytokines such as
nterleukin 1(IL-1), interleukin 6 (IL-6) and tissue necrosis fac-
or alpha (TNF) as well as c-reactive protein (CRP), and a reduced
erum level of anti-inﬂammatory cytokines including interleukin
0 (IL-10) (Baylis et al., 2013b) and IL-1ra. The factors driving
nﬂammaging are multiple (Fig. 2) and can include increased output
f pro-inﬂammatory cytokines by resting monocytes (Doyle et al.,
010; Jackaman et al., 2013; Pinke et al., 2013), reduced IL-10 pro-
uction by regulatory lymphocytes (Duggal et al., 2013), increased
diposity leading to production of pro-inﬂammatory adipokines
uch as leptin and reduced anti-inﬂammatory adipokines such as
diponectin (Lutz and Quinn, 2012), reduced physical activity with
ge (Woods et al., 2012), and senescent cells which build up with
ge and secrete pro-inﬂammatory cytokines (Coppe et al., 2010).
Neutrophils have a fundamental role in the defence against bac-
erial infections and in older adults many aspects of their function
uch as phagocytosis, superoxide production, and NET generation
re impaired with age (reviewed in Hazeldine and Lord, 2015). In
his review we focus on reduced chemotactic ability (Sapey et al.,
014). Neutrophils migrate from the blood to a site of infection or
issue damage in response to chemoattractants, moving through
issue by releasing proteases such as neutrophil elastase at their
eading edge and damaging healthy tissue in the process resulting
n inﬂammation (Cepinskas et al., 1999). Our previous work has
hown that chemotaxis is reduced in older adults making migra-
ion inefﬁcient, leading to greater tissue damage and secondary
ystemic inﬂammation (Niwa et al., 1989; Wenisch et al., 2000;
utcher et al., 2001; Hazeldine et al., 2014; Sapey et al., 2014).
Whilst investigation of the role of the immune system in frailty
nd sarcopenia lags behind similar research into ageing and age-
elated conditions, there is evidence that the immune system, and
ts dysregulation, may  play a role in both processes.
.1. Role of increased systemic inﬂammation
Multiple associations have been demonstrated between frailty
nd sarcopenia and the individual cytokine components of inﬂam-
aging, though evidence of a causal relationship remains to be
roven.
.1.1. Inﬂammatory cytokines, IL-6 and TNF˛
The potential role of IL-6 in sarcopenia is complex. This cytokine,
nitially thought to be only produced by immune cells, was eventu-
lly identiﬁed as being produced by muscle and in this context was
ermed a ‘myokine’ (Pedersen and Febbraio, 2008). In uninfected
ndividuals muscle is in fact a major source of circulating IL-6. IL-
 expression increases acutely in contracting skeletal muscle and
s released following exercise (Steensberg et al., 2000), enhanc-
ng muscle metabolism, fatty acid oxidation, and glucose uptake Reviews 36 (2017) 1–10 5
(Kelly et al., 2009). However, there is increasing evidence that IL-6
can act via the ubiquitin proteasome muscle degradation pathway,
with raised systemic IL-6 associated with increased ubiquitin pro-
tein and mRNA (DeJong et al., 2005), E3 ligase protein and mRNA
(White et al., 2012) and proteasome activity (Ebisui et al., 1995).
In addition IL-6 can induce insulin resistance which suppresses
Akt-mTOR activity and inhibits muscle synthesis (Febbraio et al.,
2004; Franckhauser et al., 2008). Another pro-sarcopenic effect of
inﬂammation is on the generation of cortisol within tissues. Corti-
sol is profoundly catabolic and can be synthesised from inactive
cortisone in tissues including muscle and bone, by the actions
of the enzyme 11HSD1 (Morgan et al., 2009). 11HSD1 activity
increases with age and is induced by cytokines including TNF and
IL-6 (Tomlinson et al., 2004). The systemic increase in inﬂammation
with age may  indirectly impact on muscle turnover via induction
of 11HSD1.
A  positive association between chronically raised serum IL-6
and TNF and frailty has been demonstrated in several epidemi-
ological studies (Leng et al., 2002; Walston et al., 2002; Leng et al.,
2004). Higher serum levels of IL-6 predict development of sarcope-
nia (Payette et al., 2003; Schaap et al., 2006) and increased IL-6 also
predicts disability and mortality, recognised outcomes of frailty and
sarcopenia (Cesari et al., 2012). In addition, high serum IL-6 and
CRP at baseline assessment have been associated with a two to
threefold greater risk of losing more than 40% of grip strength over
three years (Schaap et al., 2006). Using centenarians as a model for
‘healthy ageing’ has also given some support for a link between IL-6,
with frailty and sarcopenia in humans. Speciﬁcally, the IL-6 174GG
genotype, which is associated with higher plasma levels of IL-6, is
under-represented in centenarians (Franceschi and Bonafe, 2003).
However, a major limitation in understanding the role of inﬂam-
mation in sarcopenia is the limited number of studies that have
measured inﬂammatory cytokines, whether at the mRNA or protein
level, in human skeletal muscle with age. Two studies comparing
healthy young and old males reported 3.3 and 2.8 fold increases
in mRNA for IL-1 (Przybyla et al., 2006) and TNF (Leger et al.,
2008) for older men. A study comparing frail older adults, deﬁned
by physical function testing, with young subjects reported raised
TNF mRNA and protein in myocytes from the frail subjects. More-
over, an exercise intervention in these frail adults reduced TNF
mRNA and protein levels and improved muscle strength (Greiwe
et al., 2001). In contrast, three studies have found no differences in
skeletal muscle IL-6 mRNA with age (Hamada et al., 2005; Przybyla
et al., 2006; Trenerry et al., 2008) and two found no age-related
increase in TNF mRNA in males (Hamada et al., 2005) or females
(Raue et al., 2007).
The apparent discrepancies between studies of systemic inﬂam-
mation and sarcopenia may  indicate that it is the degree and
chronicity of inﬂammation that dictates the effect on muscle mass,
strength and quality. Thus relatively mild levels of inﬂammation
such as those seen with normal ageing or with obesity may  not
be sufﬁcient to effect loss of muscle mass or strength, but could
contribute to sarcopenia by affecting metabolic quality (Murton
et al., 2017). When systemic inﬂammation is more severe and
accompanied by inﬂammation in skeletal muscle itself, as may
be seen in frailty (Greiwe et al., 2001), then inﬂammation may
also contribute to loss of muscle mass and strength. In support of
this proposal exogenous administration of TNF to mice causes:
(1) anorexia and muscle loss, achieved via several mechanisms
including reduced amino acid availability via upregulation of lep-
tin (Grunfeld et al., 1996; Sarraf et al., 1997); (2) activation of the
transcription factor NF-B in muscle resulting in myoﬁbre; atro-
phy and activation of the ubiquitin-proteasome pathway (Li and
Reid, 2000; Ladner et al., 2003; Cai et al., 2004) and (3) suppression
of the Akt-mTOR pathway of protein synthesis (Pijet et al., 2013).
In rats, infusion of lipopolysaccharide to mimic  sepsis induces a
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hig. 3. Relationships between dysregulation of PI3k-Akt pathway in neutrophils an
f  PI3k-Akt pathway within neutrophils and muscle and frailty and sarcopenia stat
igniﬁcant systemic inﬂammatory response and increased expres-
ion of IL-6 and TNF mRNA in skeletal muscle associated with
oss of muscle mass and strength(Crossland et al., 2008). Moreover,
ampening of the inﬂammatory response in muscle, by the con-
omitant administration of glucocorticoid, preserved muscle mass
Crossland et al., 2010). TNF directly upregulates the NF path-
ay via I kinase (IKK) and induces MuRF-1 expression which
auses myoﬁbril degradation via the ubiquitin proteasome path-
ay (Li and Reid, 2000; Ladner et al., 2003).
Multiple chronic inﬂammatory conditions are associated with
uscle loss either described as sarcopenia or cachexia: can-
er, heart failure, COPD, chronic kidney disease, Crohn’s disease,
heumatoid arthritis, HIV (Evans, 2010; Biolo et al., 2014). Muscle
oss has been investigated at a cellular level in COPD, and whilst
urther research is required to conﬁrm the data, on balance there
s an increase in ubiquitin proteasome activity and a decrease in
rotein synthesis (Constantin et al., 2013). This suggests that the
nabolic and catabolic pathways utilising the intra-cellular PI3K-
kt pathway are important in the development and maintenance
f sarcopenia in chronic inﬂammatory states. Similar results have
een replicated in other chronic inﬂammatory conditions.
.1.2. Anti-inﬂammatory cytokines
IL-10, an anti-inﬂammatory cytokine, declines in the circula-
ion with age in humans (Franceschi et al., 2007; Bartlett et al.,
012). The development of an IL-10 homozygous knockout mouse
as provided an interesting and informative model of sarcopenia
nd frailty as it develops increased muscle weakness and decreased
trength with age in comparison to wild type mice (Walston et al.,
008). This mouse also has signiﬁcantly raised levels of IL-6 at
0 weeks of age (Walston et al., 2008). At 92 weeks of age these
ice also show compromised skeletal muscle quality, with reduced
keletal muscle energy metabolism in the form of reduced ATP
ux via creatine kinase, and lower free energy released during ATP
ydrolysis compared to wild type mice (Akki et al., 2014). Theseopenia and frailty. Figure depicting proposed relationships between dysregulation
mice also show reduced muscle growth and regeneration after
injury (Deng et al., 2012). These data offer one potential explanation
for why muscle strength declines more quickly than muscle mass
in sarcopenia, however there are currently few reports of associa-
tions between IL-10 and frailty or sarcopenia in humans. Only one
study has compared IL-10 expression in muscle from young and
old subjects and shown a modest increase, 1.4 fold, in IL-10 mRNA
in healthy older males (Przybyla et al., 2006) However, an IL-10
polymorphism 1082CC, associated with high serum levels of IL-
10, is over-represented in centenarians, suggesting an association
with longevity at least (Franceschi and Bonafe, 2003). It is therefore
important now to conﬁrm if IL-10 expression is reduced in skeletal
muscle from sarcopenic older adults to provide support for its role
in muscle loss and frailty in humans.
There are few studies of other anti-inﬂammatory cytokines
and their expression in skeletal muscle. One study found that
interleukin-1 receptor antagonist (IL1-ra) mRNA was increased
7.2 fold in healthy older males in comparison to younger males
(Przybyla et al., 2006) but this has not yet been conﬁrmed by oth-
ers. The authors suggested this may  be a functional response to the
elevated IL-1 mRNA also demonstrated in the healthy older males.
Fig. 2 proposes a relationship between inﬂammaging, sarcope-
nia and frailty, representing a coalescence of ideas that may
underpin the potential relationship between inﬂammaging and
sarcopenia. At present mechanistic insight cannot be given as fur-
ther research is required, especially in humans and evidence of a
direct causal relationship is thus also missing.
3.1.3. Leukocytes, sarcopenia and frailty
Age-related changes to the cells of the innate immune system
may  contribute indirectly to frailty and sarcopenia via their role
in the age-related increase in systemic inﬂammation. White cell
counts and neutrophil numbers after adjustment for the most com-
mon  confounders are raised in populations of frail older people
(Leng et al., 2007; Leng et al., 2009; Collerton et al., 2012). Higher
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eutrophil counts are associated with low levels of physical activ-
ty and frailty (Fernandez-Garrido et al., 2014) and a higher white
ell count in healthy 60 year olds can predict frailty ten years later
Baylis et al., 2013a). How such changes might affect frailty and
arcopenia is still poorly understood but we attempt to offer some
nsight here.
Neutrophils are the most abundant leukocyte in the blood and
e have shown that their chemotactic ability is greatly reduced
ith age. Consequently migration is inefﬁcient, the neutrophils
roduce more tissue damage and secondary systemic inﬂamma-
ion as they migrate through tissue (Niwa et al., 1989; Wenisch
t al., 2000; Butcher et al., 2001; Hazeldine et al., 2014; Sapey et al.,
014). Therefore it is plausible that neutrophils play a key role
n the inﬂammatory mechanisms seen in sarcopenia and frailty.
eutrophils are central to tissue repair and research has demon-
trated in a number of models of muscle injury that neutrophils
re recruited to the site of the injury within a couple of hours
Smith et al., 1998; MacIntyre et al., 2000; Quindry et al., 2003).
owever, migrating neutrophils also cause secondary damage to
ealthy muscle and studies report that muscle damage is reduced
hen functioning neutrophils are prevented from migrating to the
amaged tissue (Jolly et al., 1986; Korthuis et al., 1988). The original
tudies used an ischaemia and reperfusion model but subsequent
tudies have utilised a muscle stretch injury model and directly
isualised the muscle damage by microscopy (Brickson et al., 2003).
nefﬁcient neutrophil migration may  thus be a major contributor to
ncreased inﬂammation in older adults especially at times of muscle
amage (Fig. 3).
Recent data from our group has identiﬁed the mechanism
nderlying reduced chemotaxis in neutrophils from old donors.
naccurate chemotaxis was associated with constitutive PI3K sig-
alling and selective pharmacological inhibition of PI3K or PI3K
estored neutrophil migratory accuracy (Sapey et al., 2014). More-
ver, the reduced neutrophil chemotaxis was associated with
ncreased systemic inﬂammation in the older donors, most likely
ue to the tissue damage that occurs during neutrophil migration.
s there are inhibitors of PI3K currently in clinical trial, this offers
 novel route to therapy for immunesenescence and in theory this
ay  also improve frailty and sarcopenia states.
As muscle ages it becomes more susceptible to injury and
ertainly as a person ages dysregulation of entire systems, for exam-
le balance and cognition, result in a greater number of injuries
Campbell et al., 1981; van Doorn et al., 2003; Shavlakadze et al.,
010; Shubert, 2011). It can be postulated that muscle injury
n an older person combined with immune ageing would cause
econdary damage to healthy muscle from aberrantly migrating
eutrophils resulting in myocyte damage and apoptosis and loss of
uscle ﬁbres. This loss of muscle quality and mass could result in
he functional losses and physical weakness of frailty. Research is
ow required to acquire evidence to test this hypothesis.
. Conclusions
The historical difﬁculties of deﬁnition, measurement and mod-
lling in both sarcopenia and frailty in addition to the fundamental
ifﬁculties of investigating complex, multi-factorial syndromes
as led to a lack of information regarding the pathophysiologi-
al causes of frailty and sarcopenia. Whilst there is some limited
esearch into associations there is very little investigating more
omplex pathways attempting to link the two  syndromes. The
uggested link of increased systemic inﬂammation could explain
he relationship between sarcopenia and immunesenescence, with
berrant neutrophil migration potentially contributing to inﬂam-
aging and tissue damage associated with sarcopenia and frailty.
urther research on the cell pathways connecting inﬂammaging, Reviews 36 (2017) 1–10 7
sarcopenia and frailty would help to better understand these con-
ditions and progress to potential novel therapies for frailty and
sarcopenia which could include modulation of PI3k to correct neu-
trophil chemotaxis.
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